 Home > Active Ingredient News > Study of Nervous System > JAMA Sub-Journal: After Alzheimer’s, "no desire, no desire", the "smart medicine" that once made test addiction may be effective!

JAMA Sub-Journal: After Alzheimer’s, "no desire, no desire", the "smart medicine" that once made test addiction may be effective!

 Last Update: 2021-10-20
 Source: Internet
 Author: User

Tags

25 mg tramadol

chlordiazepoxide 25 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Neuropsychiatric symptoms (NPS) are very common in the cognitive function spectrum of the elderly.
In the development of cognitive ability, it affects half of patients with mild cognitive impairment and almost all patients with dementia
.

Neuropsychiatric symptoms have predictive value in predicting accelerated disease progression and functional decline

Neuropsychiatric symptoms (NPS) are very common in the cognitive function spectrum of the elderly.

According to reports, up to 72% of Alzheimer's (AD) patients are indifferent

JAMA

This multicenter randomized placebo-controlled clinical trial was conducted in 10 multicenter specialty clinics from August 2016 to July 2020
.

A total of 307 potential participants were screened

The results showed that of the 200 participants, 99 were assigned to methylphenidate and 101 were assigned to placebo
.

The median (quartile) age of the study participants was 76 (71-81) years; 68 (34%) were women, and 131 (66%) were men

Compared with placebo, patients treated with methylphenidate had a greater decrease in the NPI apathy score from baseline to 6 months (mean -1.

NPI score difference between the two groups during follow-up

Among them, in the first 100 days, the NPI apathy score decreased the most.
Compared with placebo, the apathy symptoms of the participants who received methylphenidate improved more than doubled (HR=2.
16; 95%CI, 1.
19-3.
91)
.

At 6 months, compared with placebo, the probability of an improvement in the AD impression score of methylphenidate was 1.

Among them, in the first 100 days, the NPI apathy score decreased the most.

In summary, methylphenidate is a safe and effective drug, which can significantly improve the indifferent symptoms of Alzheimer's disease

references:

Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial.

Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial.
Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.